Aligning with our findings, a meta-analysis of five RCTs found that PD-1/PD-L1 inhibitors led to longer times to the first clinically significant deterioration in HRQoL scores, as well as improvements in physical function and pain in patients with lung cancer [34]. The gene discussed is PDCD1; the disease is lung carcinoma.